William Wood (for Mayank Mamtani)'s questions to Altimmune Inc (ALT) leadership • Q4 2024
Question
William Wood of B. Riley Securities sought more detail on the IMPACT trial's top-line data, asking if it would include the combined endpoint of fibrosis improvement and NASH resolution and what treatment effect was needed for statistical significance. He also asked if the new indications were obesity-related.
Answer
CMO Dr. Scott Harris confirmed the readout will include both primary endpoints and the combined endpoint, stating the study is well-powered to achieve statistical significance. CEO Dr. Vipin Garg added that the new indications leverage pemvidutide's dual benefit on weight loss and liver health, as obesity is a common comorbidity across these conditions.